Abstract:The Event Based Model (EBM) is a probabilistic generative model to explore biomarker changes occurring as a disease progresses. Disease progression is hypothesized to occur through a sequence of biomarker dysregulation "events". The EBM estimates the biomarker dysregulation event sequence. It computes the data likelihood for a given dysregulation sequence, and subsequently evaluates the posterior distribution on the dysregulation sequence. Since the posterior distribution is intractable, Markov Chain Monte-Carlo is employed to generate samples under the posterior distribution. However, the set of possible sequences increases as N! where N is the number of biomarkers (data dimension) and quickly becomes prohibitively large for effective sampling via MCMC. This work proposes the "scaled EBM" (sEBM) to enable event based modeling on large biomarker sets (e.g. high-dimensional data). First, sEBM implicitly selects a subset of biomarkers useful for modeling disease progression and infers the event sequence only for that subset. Second, sEBM clusters biomarkers with similar positions in the event sequence and only orders the "clusters", with each successive cluster corresponding to the next stage in disease progression. These two modifications used to construct the sEBM method provably reduces the possible space of event sequences by multiple orders of magnitude. The novel modifications are supported by theory and experiments on synthetic and real clinical data provides validation for sEBM to work in higher dimensional settings. Results on synthetic data with known ground truth shows that sEBM outperforms previous EBM variants as data dimensions increase. sEBM was successfully implemented with up to 300 biomarkers, which is a 6-fold increase over previous EBM applications. A real-world clinical application of sEBM is performed using 119 neuroimaging markers from publicly available Alzheimer's Disease Neuroimaging Initiative (ADNI) data to stratify subjects into 6 stages of disease progression. Subjects included cognitively normal (CN), mild cognitive impairment (MCI), and Alzheimer's Disease (AD). sEBM stage is differentiated for the 3 groups (χ2p-value<4.6e-32). Increased sEBM stage is a strong predictor of conversion risk to AD (p-value<2.3e-14) for MCI subjects, as verified with a Cox proportional-hazards model adjusted for age, sex, education and APOE4 status. Like EBM, sEBM does not rely on apriori defined diagnostic labels and only uses cross-sectional data.

Machine learning-guided, big data-enabled, biomarker-based systems pharmacology: modeling the stochasticity of natural history and disease progression

A Machine Learning-Based Data Mining in Medical Examination Data: a Biological Features-Based Biological Age Prediction Model

Artificial intelligence modeling of biomarker‐based physiological age: Impact on phase 1 drug‐metabolizing enzyme phenotypes

Applications of Stochastic Process Models to Constructing Predictive Models of Alzheimer’s Disease

A Bayesian Approach to Modeling Variance of Intensive Longitudinal Biomarker Data as a Predictor of Health Outcomes

Probabilistic Clustering using Shared Latent Variable Model for Assessing Alzheimers Disease Biomarkers

Robust parametric modeling of Alzheimer's disease progression

Joint Modeling of Biomarker Cascades Along An Unobserved Disease Progression with Differentiate Covariate Effects: An Application in Alzheimer's Disease

Disease progression modelling of Alzheimer's disease using probabilistic principal components analysis

Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression

The potential for complex computational models of aging

Machine Learning in Modeling Disease Trajectory and Treatment Outcomes: An Emerging Enabler for Model‐Informed Precision Medicine

sEBM: Scaling Event Based Models to Predict Disease Progression via Implicit Biomarker Selection and Clustering

Disease Progression Modeling and Prediction through Random Effect Gaussian Processes and Time Transformation

Bayesian two-stage modeling of longitudinal and time-to-event data with an integrated fractional Brownian motion covariance structure

Model-based stratification of progression along the Alzheimer disease continuum highlights the centrality of biomarker synergies

A joint model for multiple dynamic processes and clinical endpoints: application to Alzheimer's disease

Towards Maps of Disease Progression: Biomedical Large Language Model Latent Spaces For Representing Disease Phenotypes And Pseudotime

Bayesian Joint Model with Latent Time Shifts for Multivariate Longitudinal Data with Informative Dropout

Multitask Learning of Longitudinal Circulating Biomarkers and Clinical Outcomes: Identification of Optimal Machine-Learning and Deep-Learning Models

Quantitative and Systems Pharmacology 3. Network-Based Identification of New Targets for Natural Products Enables Potential Uses in Aging-Associated Disorders